Article
Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.
Breast cancer research : BCR - 7 Apr 2014
Zhang Haiyu, Cohen Adam L, Krishnakumar Sujatha, Wapnir Irene L, Veeriah Selvaraju, Deng Glenn, Coram Marc A, Piskun Caroline M, Longacre Teri A, Herrler Michael, Frimannsson Daniel O, Telli Melinda L, Dirbas Frederick M, Matin A C, Dairkee Shanaz H, Larijani Banafshe, Glinsky Gennadi V, Bild Andrea H, Jeffrey Stefanie S
Abstract excerpt
INTRODUCTION: Triple-negative breast cancer (TNBC) is aggressive and lacks targeted therapies. Phosphatidylinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathways are frequently activated in TNBC patient tumors at the genome, gene expression and protein levels, and mTOR inhibitors have been shown to inhibit growth in TNBC cell lines. We describe a panel of patient-derived xenografts representing...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.